Cobas 6000 and 8000

Manufactured by Roche

Sourced in Sweden

The Cobas 6000 and 8000 are automated, random-access, modular laboratory analyzers developed by Roche. They are designed for high-throughput clinical chemistry and immunoassay testing in a wide range of clinical applications. The Cobas 6000 and 8000 consist of various modules that can be configured to meet specific laboratory needs.

Automatically generated - may contain errors

Lab products found in correlation

Ca125 2, by Roche (1 mentions)

Spelling variants of this product

Cobas 8000 (757 citations) Cobas 6000 (699 citations) Cobas 6000/8000 (9 citations)

3 protocols using cobas 6000 and 8000

Cardiovascular Risk Biomarkers Assessment

Check if the same lab product or an alternative is used in the 5 most similar protocols

Fasting morning blood samples were obtained from all participants and analyzed for hemoglobin (Hb), glycated hemoglobin (HbA1c), N-terminal pro-brain natriuretic peptide (NT-proBNP), low-density lipoprotein (LDL), high-density lipoprotein (HDL), total cholesterol, triglycerides, creatinine, and C-reactive protein (CRP). The samples were analyzed using Cobas 6000 and 8000 (Roche Diagnostics, Mannheim, Germany).
Blood pressure was measured in the supine position. BSA and BMI was calculated from self-reported weight and height. Obesity and metabolic syndrome were defined in accordance with guidelines from the American Heart Association [9 (link)]. Hypertension was defined as either the use of antihypertensive medication or a systolic blood pressure ≥ 140 mmHg or a diastolic blood pressure ≥ 90 mmHg. Hypercholesterolemia was defined as either a total cholesterol of > 7 mmol/L or LDL ≥ 3.6mmol/L or the use of lipid-lowering medication [10 (link)]. All participants were assessed for cardiovascular risk using the Framingham Risk Score for Hard Coronary Heart Disease [11 (link)].

Bjerring A.W., Smeland K.H., Stokke T., Haugaa K.H., Holte E., Rösner A., Kiserud C.E., Edvardsen T, & Sarvari S.I. (2024). Long-term cardiac effects of modern treatment for Hodgkin’s lymphoma. Cardio-oncology, 10, 19.

+ Open protocol

+ Expand

Cardiovascular Risk Factors Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

Blood samples were obtained from all participants at Oslo University Hospital. In all patients, total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides, C-reactive protein (CRP), and N-terminal pro-brain natriuretic peptide (NT-proBNP) were analysed on Cobas 6000 and 8000 (Roche Diagnostics, Mannheim, Germany).
Blood pressure was measured in the supine position before and after the echocardiography. The average of the two measurements was used. Weight and height were self-reported. Metabolic syndrome and obesity were defined in accordance with guidelines from the American Heart Association.²³ (link) Hypercholesterolaemia was defined as the use of lipid-lowering medication, total cholesterol of >7 mmol/L, or LDL ≥ 3.6 mmol/L. Hypertension was defined as systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or the use of antihypertensive medication.²⁴ (link)

Bjerring A.W., Fosså S.D., Haugnes H.S., Nome R., Stokke T.M., Haugaa K.H., Kiserud C.E., Edvardsen T, & Sarvari S.I. (2020). The cardiac impact of cisplatin-based chemotherapy in survivors of testicular cancer: a 30-year follow-up. European Heart Journal Cardiovascular Imaging, 22(4), 443-450.

+ Open protocol

+ Expand

Serum Biomarkers for Gynecological Malignancies

Check if the same lab product or an alternative is used in the 5 most similar protocols

Serum for the analysis of CA125 (U/mL), HE4 (/L), creatinine (μmol/L) and pro-BNP (ng/L) were collected at the time of enrollment prior to surgery, centrifuged and stored in 4 °C before being shipped, according to standardized procedures, to Sahlgrenska University hospital as previously described [2] . The coded samples were analyzed at an accredited central laboratory (ISO 15189) Sahlgrenska University hospital in three separate batches. CA125, HE4, NT-pro-BNP and creatinine were analyzed using the Elecsys HE4 and Elecsys CA125 II with the electrochemiluminescence (ECLIA) technique (Cobas 6,000 and 8,000, RocheDiagnostics Scandinavia, Stockholm, Sweden) [2] . Recommended cut-offs according to the manufacturer were used in the study; CA125 > 35 U/mL, HE4 pre-M > 70 pmol/L, HE4 post-M > 140 pmol/L [23] . Glomerular filtration rate (eGFR) was estimated using creatinine as a measure of renal function using the revised Lund-Malmö equation [24] . Continuous levels of eGFR were used as a measure for impaired kidney function and continuous levels of NT-pro-BNP were used as a measure of heart disease in the multivariable analyses.

Lycke M., Ulfenborg B., Malchau Lauesgaard J., Kristjansdottir B, & Sundfeldt K. (2021). Consideration should be given to smoking, endometriosis, renal function (eGFR) and age when interpreting CA125 and HE4 in ovarian tumor diagnostics. Clinical chemistry and laboratory medicine, 59(12).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!